- Visibility 152 Views
- Downloads 119 Downloads
- Permissions
- DOI 10.18231/j.ijpp.13260.1758801291
-
CrossMark
Prescribing patterns of antiplatelet drugs in patients with cardiovascular and cerebrovascular diseases
- Author Details:
-
Sumit Choudhary
-
Anurag Kumar *
-
Ravi Shankar Dwivedi
-
Tushar Arora
Sumit Choudhary
Anurag Kumar *
Background: Antiplatelet drugs play a crucial role in the management of the Cardiovascular and Cerebrovascular disease. This aim is to provide Evidence based treatment in the prevention of the worldwide health threat of this disease.
Objective: The Objectives is to assess the current prescribing practices of antiplatelet drugs for patients with cardiovascular and cerebrovascular diseases and to identify potential factors influencing prescribing patterns in patient with comorbidities.
Materials and Methods: At Superspeciality hospital, a 6-months cross sectional Prospective observational Research was conducted on impatient patient of Cardiology & Neurology Department,145 Prescription were examined and deemed inoperative.
Result: The study shows that cardiovascular and cerebrovascular diseases are more common in men (62.1%) than women (37.9%), with a sample of 90 males and 55 females. Cardiovascular diseases predominate over cerebrovascular diseases in both rural and urban areas, with a slightly higher incidence in urban populations. Young adults (18-30) have minimal risk, which increases with age, particularly among older adults; 11 individuals have both conditions. The most prescribed antiplatelet therapy is Aspirin and Ticagrelor (79.03%), followed by Aspirin and Clopidogrel (19.35%), with Clopidogrel and Aspirin Av being the least common (1.66%). A significant overlap of comorbidities (65%) is noted due to shared risk factors, and 78% of patients have a history of cardiovascular or cerebrovascular events. Patients with diabetes, CKD, and AKI are at higher risk for thrombotic and bleeding complications, requiring careful monitoring of antiplatelet therapy. In cases of hypothyroidism and pulmonary oedema, Aspirin is the most frequently used antiplatelet (49%), followed by Clopidogrel (20%), Ticagrelor (17%), and Prasugrel (12.4%).
Conclusion: The study provides valuable understanding of these disease, effectiveness of multiple antiplatelet therapies, & impact of comorbidities on the treatment option.
References
- Knowles RB, Warner TD (2019). Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy. Pharmacol Ther. 2019;193, 83–90. doi:10.1016/j.pharmthera.2018.08.004
[Google Scholar] - Fitzgerald DJ, FitzGerald GA. Historical Lessons in Translational Medicine. Circ. Res. 2013;112(1):174–194. doi: 10.1161/ circresaha.111.300271
- Sharifi-Rad J, Sharopov F, Ezzat SM, Zam W, Ademiluyi AO, Oyeniran OH, et al. An updated review on glycoprotein IIb/IIIa inhibitors as antiplatelet agents: basic and clinical perspectives. High Blood Press. & Cardiovasc. Prev. 2023;30(2):93-107. doi: 10.1007/s40292-023-00562-99
[Google Scholar] - Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann. Transl. Med. 2016;4(13):256-256. doi: 10.21037/ atm.2016.06.33
- Chong B, Jayabaskaran J, Jauhari SM, Chan SP, Goh R, Kueh MTW, et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur. J. Prev. Cardiol. 2025;32(11):1001-1015. doi: 10.1093/eurjpc/zwae281
[Google Scholar] - Del Giovane C, Boncoraglio GB, Bertù L, Banzi R, Tramacere I. Antiplatelet drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. BMC Neurol. 2021;21(1). doi: 10.1186/ s12883-021-02341-2
- Price AJ, Wright FL, Green J, Balkwill A, Kan SW, Yang TO, et al. Differences in risk factors for 3 types of stroke. Neurology. 2018;90(4). doi: 10.1212/wnl.0000000000004856
[Google Scholar] - Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT, Psaty BM. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology. 2004;63(10):1868-1875. doi: 10.1212/01.wnl.0000144282.42222.da
[Google Scholar] - Kundu J, James KS, Hossain B, Chakraborty R. Gender differences in premature mortality for cardiovascular disease in India, 2017–18. BMC Public Health 2023;23(1). doi: 10.1186/s12889-023-15454-9
[Google Scholar] - Rodgers JL, Jones J, Bolleddu SI, Vanthenapalli S, Rodgers LE, Shah K, et al. Cardiovascular risks associated with gender and Aging. J. Cardiovasc. Dev. Dis. 2019;6(2):19. doi: 10.3390/ jcdd6020019
- Samuel P, Antonisamy B, Raghupathy P, Richard J, Fall CH. Socio- economic status and cardiovascular risk factors in rural and urban areas of Vellore, Tamilnadu, South India. Int. J. Epidemiology. 2012;41(5):1315-1327. doi: 10.1093/ije/dys001
[Google Scholar] - Kendir C, van den Akker M, Vos R, Metsemakers J. Cardiovascular disease patients have increased risk for comorbidity: A cross-sectional study in the Netherlands. Eur. J. Gen. Pract. 2018;24(1):45-50. doi: 10.1080/13814788.2017.1398318
[Google Scholar] - Vazzana N, Ranalli P, Cuccurullo C, Davì G. Diabetes mellitus and thrombosis. Thromb. Res. 2012;129(3):371-377. doi: 10.1016/j
[Google Scholar] thromres.2011.11.052 - Saeed Z, Sirolli V, Bonomini M, Gallina S, Renda G. Hallmarks for Thrombotic and Hemorrhagic Risks in Chronic Kidney Disease Patients. Int. J. Mol. Sci. 2024;25(16):8705. doi: 10.3390/ ijms25168705
- Mansurova J, Kassymova A, Kozhabayeva A, Karazhanova L. (2025). Personalized antiplatelet therapy in a post-PCI patient with high bleeding risk. Signa Vitae , 21(3), 114–119. https://doi. org/10.22514/sv.2025.044
[Google Scholar]